BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2013808)

  • 21. Extranodal malignant lymphoma: detection with FDG PET versus CT.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Merkle E; Frickhofen N; Reske SN
    Radiology; 1998 Feb; 206(2):475-81. PubMed ID: 9457202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation of ¹⁸F-FDG uptake with tumor-proliferating antigen Ki-67 expression in aggressive lymphoma].
    Liang Y; Wu N; Fang Y; Huang WT; Zhang H; Zheng R; Zhang WJ; Liu Y; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):356-60. PubMed ID: 24054012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of 18Fluorine-deoxyglucose (FDG) positron emission tomography in the management of lymphomas].
    Massardo V T; Canessa G J; Jofré M MJ; González E P; Humeres A P; Sierralta G P
    Rev Med Chil; 2006 Jul; 134(7):910-9. PubMed ID: 17130976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [18F-FDG uptake of lymphoma lesions of various histological subtypes].
    Ma LF; Fan W
    Ai Zheng; 2009 Apr; 28(4):425-30. PubMed ID: 19622306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in the treatment of Hodgkin's disease and malignant non-Hodgkin's lymphoma].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S88-95. PubMed ID: 12739340
    [No Abstract]   [Full Text] [Related]  

  • 26. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography.
    Rosenfeld SS; Hoffman JM; Coleman RE; Glantz MJ; Hanson MW; Schold SC
    J Nucl Med; 1992 Apr; 33(4):532-6. PubMed ID: 1552337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
    Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
    J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Lymphography in malignant lymphomas (report of 200 cases)].
    Blaudow K
    Radiobiol Radiother (Berl); 1970; 11(5):559-79. PubMed ID: 4928133
    [No Abstract]   [Full Text] [Related]  

  • 29. The use of PET-18FDG imaging in the clinical evaluation of head and neck lymphoma.
    Walsh RM; Wong WL; Chevretton EB; Beaney RP
    Clin Oncol (R Coll Radiol); 1996; 8(1):51-4. PubMed ID: 8688363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary muscle lymphoma: clinical and imaging findings.
    Lee VS; Martinez S; Coleman RE
    Radiology; 1997 Apr; 203(1):237-44. PubMed ID: 9122401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG-PET for the evaluation of tumor viability after anticancer therapy.
    Okada J; Oonishi H; Yoshikawa K; Imaseki K; Uno K; Itami J; Arimizu N
    Ann Nucl Med; 1994 May; 8(2):109-13. PubMed ID: 8074956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study.
    Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [18F]fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin.
    Minn H; Leskinen-Kallio S; Lindholm P; Bergman J; Ruotsalainen U; Teräs M; Haaparanta M
    J Comput Assist Tomogr; 1993; 17(1):115-23. PubMed ID: 8419418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spontaneous regression of follicular, mantle cell, and diffuse large B-cell non-Hodgkin's lymphomas detected by FDG-PET imaging.
    Kumar R; Bhargava P; Zhuang H; Yu JQ; Schuster SJ; Alavi A
    Clin Nucl Med; 2004 Nov; 29(11):685-8. PubMed ID: 15483478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
    Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
    Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18F-fluorodeoxyglucose positron emission tomography.
    Khandani AH; Dunphy CH; Meteesatien P; Dufault DL; Ivanovic M; Shea TC
    Nucl Med Commun; 2009 Aug; 30(8):594-601. PubMed ID: 19536037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Role of 18F-FDG PET in tumor grading and evaluating effectiveness of therapy in malignant lymphomas].
    Tlostanova MS; Tiutin LA; Ryzhkova DV; Il'in NV; Ivanova EI; Vinogradova IuN; Ivanova AA; Savchenko ON
    Vopr Onkol; 2008; 54(4):475-9. PubMed ID: 18942403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of PET imaging in lymphoma.
    Burton C; Ell P; Linch D
    Br J Haematol; 2004 Sep; 126(6):772-84. PubMed ID: 15352980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer.
    Lindholm P; Leskinen-Kallio S; Minn H; Bergman J; Haaparanta M; Lehikoinen P; Någren K; Ruotsalainen U; Teräs M; Joensuu H
    J Nucl Med; 1993 Oct; 34(10):1711-6. PubMed ID: 8410288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [FDG-PET on the day after first chemotherapy in malignant lymphoma].
    Yamane T; Daimaru O; Itoh S; Nagata T; Yoshiya K; Itoh S; Uchida H; Shinai T; Imai T; Ohishi H
    Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Dec; 62(14):839-42. PubMed ID: 12607955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.